Audio Journal of Oncology
SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclusions drawn from the Alliance North American Intergroup Study A041202 reported at …
SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irreversible inhibitor of Bruton’s tyrosine kinase [BTK]) combined with the anti-CD 20 …
SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irreversible inhibitor of Bruton’s tyrosine kinase [BTK]) combined with the anti-CD 20 …
Volume 16 Number 6 (March 15th, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
Chemotherapy Foundation Symposium, November 7-10, 2007, New York
Nonmyeloablative
Abstract 349
Sandra Horning, Stanford University Medical Center
It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therapy in patients with advanced follicular lymphoma. However, the use of rituximab maintenance, after induction …
Vincent Rajkumar, Divison of Hematology, Mayo Clinic
At a section of the hematology meeting talking about newly diagnosed multiple myeloma and the evolving treatments, Vincent Rajkumar discussed new agents such as lenolidamide and thalidomide. Audio Medica asked him …
Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York
Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAHA which targets BCL-6 in the tumor preventing it’s anti-apoptotic influence; the other …